Use of a pharmaceutical composition containing Epidermal Growth Factor (EGF) for diabetic foot amputation prevention

Use of epidermal growth factor (EGF) in a composition for treating a lesion, ischemic or caused by reperfusion, in a diabetic patient, by local infiltration into the tissues that form the borders and base of the lesion, is new. An independent claim is also included for a pharmaceutical composition (...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	NEOBALIS FRANCO PEREZ, JORGE SOTOLONGO PENA, CALIXTO VALDES PEREZ, LARISSA CHACON CORVEA, GERARDO E GUILLEN NIETO, JOSE I. FERNANDEZ MONTEQUIN, HAYDEE GERONIMO PEREZ, LEONARDO CANAN-HADEN FRIAS, HECTOR SANTANA MILIAN, LUIS HERRERA MARTINEZ, INGRID ROJAS CONSTANTIN, JOSE FERNANDEZ MONTEQUIN, JORGE BERLANGA ACOSTA, GERARDO E. GUILLEN NIETO
Format:	Patent
Sprache:	eng
Schlagworte:	CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Use of epidermal growth factor (EGF) in a composition for treating a lesion, ischemic or caused by reperfusion, in a diabetic patient, by local infiltration into the tissues that form the borders and base of the lesion, is new. An independent claim is also included for a pharmaceutical composition (liquid or freeze-dried) for treating the specified lesions that contains 10-1000 Microg/ml of EGF combined with at least one of fibronectin; raffinose; poly(ethyleneimine); an isoflavonoid (e.g. rutin); lidocaine; adenosine or guanosine triphosphates, or their salts; nicotinamide; L-Arg or heparin salt. ACTIVITY : Antidiabetic; Vulnerary. MECHANISM OF ACTION : Stimulation of cell proliferation.